Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | XPO1 | O14980 | 3/20 | 0.37 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.37 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.37 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.37 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ASPH | Q12797 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20303763 | 0.84 | XPO1 (0.39) | KMOALDH1A1KMT2AMEN1XPO1 | |
| SCHEMBL11832350 | 0.82 | HPGD (0.50) | KMOALDH1A1HPGDKMT2AMEN1 | |
| SCHEMBL19584143 | 0.81 | CCR9 (0.39) | ALDH1A1DAOKMT2AMEN1KDM4E | |
| SCHEMBL16648695 | 0.80 | ALDH1A1 (0.43) | ALDH1A1KMT2AMEN1XPO1KCNQ3 | |
| SCHEMBL16648685 | 0.80 | NOTUM (0.45) | ALDH1A1KMT2AXPO1KDM4ENOTUM | |
| SCHEMBL18149694 | 0.78 | SORT1 (0.43) | KMOALDH1A1HPGDDAO | |
| SCHEMBL19584011 | 0.76 | HDAC4 (0.52) | ALDH1A1HPGDKMT2AMEN1KDM4E | |
| Clopyralid SCHEMBL29371357 | 0.76 | KMT2A (0.50) | ALDH1A1KMT2AMEN1KDM4ENAPRT | |
| Clopyralid SCHEMBL54779 | 0.76 | KMT2A (0.50) | ALDH1A1KMT2AMEN1KDM4ENAPRT | |
| Clopyralid SCHEMBL8535196 | 0.76 | KMT2A (0.50) | ALDH1A1KMT2AMEN1KDM4ENAPRT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140221360-A1 | USE OF AMINODIHYDROTHIAZINES FOR THE TREATMENT OR PREVENTION OF DIABETES | HOFFMANN-LA ROCHE INC. (US) | 2014-08-07 | — | — | US | claimed |
| US-20130096107-A1 | USE OF AMINODIHYDROTHIAZINES FOR THE TREATMENT OR PREVENTION OF DIABETES | HOFFMANN-LA ROCHE INC. (US) | 2013-04-18 | — | — | US | claimed |
| EP-2475658-A1 | 2 -AMINODIHYDRO [1, 3]THIAZINES AS BACE 2 INHIBITORS FOR THE TREATMENT OF DIABETES | F. Hoffmann-La Roche AG (CH) | 2012-07-18 | — | — | EP | claimed |
| CN-102482268-A | 2-Aminodihydro [1,3] thiazines as BACE2 inhibitors for the treatment of diabetes | HOFFMANN LA ROCHE | 2012-05-30 | — | — | CN | claimed |
| CN-102421760-A | Dihydropyrimidinones useful as BACE2 inhibitors | HOFFMANN LA ROCHE | 2012-04-18 | — | — | CN | claimed |
| US-20110065695-A1 | USE OF AMINODIHYDROTHIAZINES FOR THE TREATMENT OR PREVENTION OF DIABETES | HOFFMANN-LA ROCHE, INC. | 2011-03-17 | — | — | US | claimed |
| WO-2010128058-A1 | DIHYDROPYRIMIDINONES FOR USE AS BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-11 | — | — | WO | claimed |
| US-20100286158-A1 | DIHYDROPYRIMIDINONES | HOFFMANN-LA ROCHE, INC. | 2010-11-11 | — | — | US | claimed |
| EP-3558298-B1 | ANTIDIABETIC SPIROCHROMAN COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| WO-2024191268-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 현대약품 주식회사 | 2024-09-19 | — | — | WO | disclosed |
| EP-3455224-B1 | SUBSTITUTED 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRIDINE-3(2H)-ONES AND 2,5,6,7-TETRAHYDRO-3H-PYRROLO[2,1-C][1,2,4]TRIAZOL-3-ONES, AND USE THEREOF | BAYER AG (DE) | 2024-03-27 | — | — | EP | disclosed |
| CN-109476658-B | Substituted 5,6,7, 8-tetrahydro [1,2,4] triazolo [4,3-a ] pyridin-3 (2H) -ones and 2,5,6, 7-tetrahydro-3H-pyrrolo [2,1-c ] [1,2,4] triazol-3-ones and uses thereof | 拜耳公司 | 2021-08-10 | — | — | CN | disclosed |
| US-10968232-B2 | Antidiabetic spirochroman compounds | MERCK SHARP & DOHME CORP. (US) | 2021-04-06 | — | — | US | disclosed |
| US-10722501-B2 | Substituted 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-A]pyridine-3(2H)-ones and 2,5,6,7-tetrahydro-3H-pyrrolo[2,1-C][1,2,4]triazol-3-ones, and use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2020-07-28 | — | — | US | disclosed |
| US-20110065695-A1 | USE OF AMINODIHYDROTHIAZINES FOR THE TREATMENT OR PREVENTION OF DIABETES | HOFFMANN-LA ROCHE, INC. | 2011-03-17 | — | — | US | disclosed |
| WO-2011029803-A1 | 2 -AMINODIHYDRO [1, 3] THIAZINES AS BACE 2 INHIBITORS FOR THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-17 | — | — | WO | disclosed |
| WO-2010128058-A1 | DIHYDROPYRIMIDINONES FOR USE AS BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-11 | — | — | WO | disclosed |
| US-20100286158-A1 | DIHYDROPYRIMIDINONES | HOFFMANN-LA ROCHE, INC. | 2010-11-11 | — | — | US | disclosed |
| WO-2010108903-A1 | 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-09-30 | — | — | WO | disclosed |
| US-20100249124-A1 | 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096107-A1 | USE OF AMINODIHYDROTHIAZINES FOR THE TREATMENT OR PREVENTION OF DIABETES | SLC5A2, SLC5A1, GLP1R | KMO 818/4885ALDH1A1 248/4885HPGD 483/4885 |
| US-20140221360-A1 | USE OF AMINODIHYDROTHIAZINES FOR THE TREATMENT OR PREVENTION OF DIABETES | SLC5A2, SLC5A1, GLP1R | KMO 818/4885ALDH1A1 248/4885HPGD 483/4885 |
| US-10968232-B2 | Antidiabetic spirochroman compounds | GPR119, GPR52, GPR55 | KMO 3566/4885ALDH1A1 1981/4885HPGD 1573/4885 |
| US-20100249124-A1 | 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | NR3C1, NR3C2, MC2R | KMO 433/4885ALDH1A1 725/4885HPGD 2335/4885 |
| US-20110065695-A1 | USE OF AMINODIHYDROTHIAZINES FOR THE TREATMENT OR PREVENTION OF DIABETES | SLC5A2, SLC5A1, GLP1R | KMO 818/4885ALDH1A1 248/4885HPGD 483/4885 |
| US-10722501-B2 | Substituted 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-A]pyridine-3(2H)-ones and 2,5,6,7-tetrahydro-3H-pyrrolo[2,1-C][1,2,4]triazol-3-ones, and use thereof | PTGIS, CYP11B2, IL1B | KMO 132/4885ALDH1A1 604/4885HPGD 156/4885 |
| US-20100286158-A1 | DIHYDROPYRIMIDINONES | BACE2, BACE1, PSEN2 | KMO 3166/4885ALDH1A1 563/4885HPGD 2099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.